Oxysterols Receptor Lxr-Beta Market Size, Definition, Treatment, Symptoms, Causes, Pipeline Review, H1 2016

Submitted by: Submitted by

Views: 10

Words: 1152

Pages: 5

Category: Science and Technology

Date Submitted: 10/19/2016 12:48 AM

Report This Essay

Oxysterols Receptor LXR-Beta Market Share, Size, Treatment,

Symptoms, Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Oxysterols Receptor LXR-Beta (Liver X Receptor Beta or Nuclear Receptor NER or Nuclear

Receptor Subfamily 1 Group H Member 2 or NR1H2 or LXRB) - Pipeline Review, H1 2016', provides in depth

analysis on Oxysterols Receptor LXR-Beta (Liver X Receptor Beta or Nuclear Receptor NER or Nuclear Receptor

Subfamily 1 Group H Member 2 or NR1H2 or LXRB) targeted pipeline therapeutics.

The report provides comprehensive information on the Oxysterols Receptor LXR-Beta (Liver X Receptor Beta or

Nuclear Receptor NER or Nuclear Receptor Subfamily 1 Group H Member 2 or NR1H2 or LXRB), targeted

therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of

administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the

therapeutics, its complete research and development history and latest news and press releases. Additionally, the

report provides an overview of key players involved in Oxysterols Receptor LXR-Beta (Liver X Receptor Beta or

Nuclear Receptor NER or Nuclear Receptor Subfamily 1 Group H Member 2 or NR1H2 or LXRB) targeted

therapeutics development and features dormant and discontinued projects.

Browse Ongoing Reports @ http://www.radiantinsights.com/research/oxysterols-receptor-lxr-beta

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and

nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's

proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor

presentations and featured press releases from company/university sites and industry-specific third party sources.

Drug profiles featured in the report undergoes periodic review following a stringent set of processes to...